

**UNAUDITED STANDALONE FINANCIAL RESULTS (PROVISIONAL) FOR THE QUARTER
ENDED SEPTEMBER 30, 2014.**

(Rs. In Lacs)

SR. NO.	PARTICULARS	Quarter ended & year to the date			30/06/2014 (Audited)
		As on 30/09/2014	As on 30/06/2014	As on 30/09/2013	
1	Net Sales / Income from Operations	32,491.62	34,675.87	31,540.56	131,376.83
	Total Income	32,491.62	34,675.87	31,540.56	131,376.83
2	Total Expenditure				
	a) (Increase)/Decrease in Stock in Trade	(1,849.85)	(3,035.88)	(718.34)	(6,221.38)
	b) Consumption of Materials	23,104.69	26,577.02	22,568.59	94,808.62
	c) Purchases of Trading Goods	5,529.04	5,458.02	5,210.11	22,687.57
	d) Employees Cost	660.28	654.29	519.62	2,307.62
	e) Depreciation	302.42	298.70	403.28	1,535.44
	f) Other Expenditure	1,192.34	593.55	439.06	2,088.53
	Total	28,938.92	30,545.70	28,422.32	117,206.40
3	Profit from Operations before Exchange Rate Difference, Other Income, Interest & Exceptional Items (1 - 2)	3,552.70	4,130.17	3,118.24	14,170.43
4	Other Income	106.28	112.83	20.10	167.71
5	Profit from Operations before Interest & Exceptional Items (3 + 4)	3,658.98	4,243.00	3,138.34	14,338.14
6	Interest	1,396.79	1,417.92	1,129.02	5,313.78
7	Profit after Interest but before Exception items (5-6)	2,262.19	2,825.08	2,009.32	9,024.36
8	Exception Items	(139.01)	(145.31)	(126.51)	548.98
9	Profit (+)/Loss(-) from Ordinary Activities before tax (7+8)	2,123.18	2,679.77	1,882.81	8,475.38
10	Tax Expenses	312.68	644.52	338.91	1,513.66
11	Net Profit before ordinary activities (8 - 9)	1,810.50	2,035.25	1,543.90	6,961.72
12	Extra Ordinary Items (Net of Tax)	-	-	-	-
13	Net Profit after Taxes (10 - 11)	1,810.50	2,035.25	1,543.90	6,961.72
14	Paid up Equity Share Capital (Face value of Rs.10/- each)	2,111.38	2,111.38	1,055.69	2,111.38
15	Reserves excluding Revaluation Reserves	-	33,327.88	-	33,327.04
16	Earning Per Shares (Before Extra Ordinary Item)				
	i) Basic	1.71	1.93	14.62	6.59
	ii) Diluted E. P. S	1.18	1.36	13.96	4.65
17	Earning Per Shares (After Extra Ordinary Item)				
	i) Basic	1.71	1.93	14.62	6.59
	ii) Diluted E. P. S	1.18	1.36	13.96	4.65

Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001

Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.
Tel. :91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com
www.sharonbio.com

Part -II


SR. NO.	PARTICULARS	Quarter ended & Year to the date			30/06/2014 (Audited)
		As on 30/09/2014	As on 30/06/2014	As on 30/09/2013	
(A)	Aggregate of Public Shareholdings				
	No. of Shares	42,017,020	42,017,020	4,194,125	42,017,020
	Percentage of Shareholdings	39.80%	39.80%	39.73%	39.80%
18	Promoters & promoter group Shareholding				
	a) Pledged / Encumbered				
	- Number of Shares	5,000,000	5,000,000	327,500	5,000,000
	- Percentage of Shares	7.87%	7.87%	5.43%	7.87%
	(as a % of the total shareholding of promoter & promoter group)				
	- Percentage of Shares	4.74%	4.74%	3.10%	4.74%
	(as a % of the total share capital of the Company)				
	b) Non-encumbered				
	- Number of Shares	58,551,980	58,551,980	6,035,275	58,551,980
	- Percentage of Shares	92.13%	92.13%	94.85%	92.13%
	(as a % of the total shareholding of promoter & promoter group)				
	- Percentage of Shares	55.46%	55.46%	57.17%	55.46%
	(as a % of the total share capital of the Company)				

Notes:-

- 1) The above results for the quarter ended September 30, 2014 have been reviewed by the Audit Committee and were taken on record by the Board of Directors in its meeting held on November 13, 2014
- 2) The "Limited Review" required under clause 41 of listing agreement has been done by statutory auditors of the Company.
- 3) The Company has provided for Foreign Exchange (Loss)/Gains under Exception Items due to exchange differences arising during the periods on foreign currency contracts and borrowings including Foreign Currency Convertible Bonds and interest for the current quarter.
- 4) Previous years figures have been regrouped and recast wherever necessary.
- 5) During the Quarter company has incurred major expenses for UKMHRA and US-FDA approvals, which has been clubbed in other expenses.
- 6) Diluted EPS has been calculated not considering the issuance of Dividend warrants as on 22/10/2014 to the promoter and promoters group which is falling after the reporting period e.g 30/09/2014.
- 7) Information on investor complaints for the quarter ended September 30, 2014 (in nos.)

Opening Balance of Complaints	Received during the Quarter	Disposed Off during the Quarter	Closing Balance
NIL	4	4	NIL

By order of the Board,
For Sharon Bio-Medicine Ltd.


Sayita Gowda
Managing Director.

Place : Mumbai.
Date : 13.11.2014

Adm. Off. : 312, C Wing, BSEL Tech Park, Sector - 30(A), Vashi, Navi Mumbai - 400 705.
Tel.: 91 22 - 67944000, Fax : 91 22 - 67944001

Head Office : Plot No. 163, Smt Janakidevi Public School Rd., SVP Nagar, Andheri (West), Mumbai - 400 053.
Tel. :91 22 26323192 / 93 / 94 Fax : 26323140 E-mail : info@sharonbio.com
www.sharonbio.com

Caring for relationships CIN No. L24110MH1939PLC052251